Aerin Medical Launches Next-Generation Device for Chronic Rhinitis Relief

Introduced amid expanding payor coverage, including recent UnitedHealthcare Medicare Advantage approval, the RhinAer+^™ Stylus builds on market-leading technology

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the launch of its next-generation RhinAer^® device as well as UnitedHealthcare’s Medicare Advantage policy now covering RhinAer for treatment of the posterior nasal nerve (CPT 31242) effective immediately. The temperature- and impedance-controlled radiofrequency RhinAer+ device treats the posterior nasal nerve (PNN) and comprehensively targets multiple anatomic contributors to chronic rhinitis, a chronic condition with substantial adverse health impact, along with sleep quality and worker productivity consequences.

The RhinAer+ Stylus is designed to enhance procedural efficiency and patient comfort. The enhancements include a low-profile atraumatic tip that improves access and visibility and a reinforced malleable shaft that provides tactile feel for tissue apposition and greater support in challenging anatomy. It also features an ergonomic handle that enables consistent control for bilateral treatment. The launch of RhinAer+ demonstrates Aerin Medical’s ongoing commitment to advancing innovation for surgeons treating patients with chronic and debilitating nasal conditions.

“The development of this product was guided by extensive physician feedback, informed by RhinAer experience in over 50,000 cases, and leveraged a proven platform characterized in 20 peer-reviewed publications,” said Matt Brokaw, President and CEO of Aerin Medical. “With expanded coverage from Cigna and UnitedHealthcare Medicare Advantage and multiple multi-year studies confirming sustained results with RhinAer technology, we’re seeing continued validation from both the clinical and payor communities.”

“RhinAer+ is a meaningful advancement in how physicians like me treat chronic rhinitis,” said Mary Ashmead, MD, board-certified otolaryngologist at ENT Southlake. “The enhancements allow us to better tailor treatment for our patients, helping more of them experience lasting relief without ineffective cycles of medication or invasive surgery.”

For more information about RhinAer technology, visit: https://rhinaer.com/hcp/

About RhinAer

Using temperature- and impedance-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit www.RhinAer.com.

About Aerin Medical

Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer^® for nasal airway obstruction and RhinAer^® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 175,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.